OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01 Other Events.
OWC Pharmaceutical Research Corp. (“OWC”) through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., announces that it has been granted a patent in the Czech Republic covering its topical formulations for skin disorders.
The patent, “Utility model no. 32207, CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS” will be valid for a period of up to ten years in the Czech Republic. ,The patent discloses a pharmaceutical topical composition comprising cannabidiol (CBD) or a derivative thereof and Tetrahydrocannabinol (THC) or a derivative thereof for treatment of skin disorders, as well as methods of treatment or prevention, of dermatologic conditions and especially inflammatory skin pathologies especially targeting Psoriasis. The patent application has also been filed in additional countries throughout the world and has already issued in Australia.
About OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.
